Stage IIB and IIC melanoma: lines of therapy
4 standard-of-care settings across 2 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.
Screening, prevention and diagnosis
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Diagnosis and surgery | Wide local excision with margins set by thickness and sentinel lymph node biopsy for primaries over 0.8 mm or with ulceration. | NCCN Guidelines: Melanoma: Cutaneous | 68 | |
| All comers | Surveillance | Skin and nodal examination and, for higher-risk disease, imaging at intervals; patient education on self-examination. | NCCN Guidelines: Melanoma: Cutaneous | 32 |
Early / localised
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Adjuvant, stage IIB or IIC | One year of pembrolizumab (KEYNOTE-716) or nivolumab (CheckMate 76K), or observation after a shared decision about a modest benefit and immune side effects. | NCCN Guidelines: Melanoma: Cutaneous | 98 | |
| All comers | Adjuvant vaccine (emerging) | Intismeran autogene with pembrolizumab met its endpoints in INTerpath-001, which included stage IIB and IIC; regulatory review pending. | 89 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.